Objective: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) disease remains a significant unmet medical need. Recent small cohort studies indicate that metformin, the world's most commonly prescribed oral hypoglycemic agent, may limit AAA enlargement. We sought to validate these preliminary observations at a population level.
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Objective: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) disease remains a significant unmet medical need. Recent small cohort studies indicate that metformin, the world's most commonly prescribed oral hypoglycemic agent, may limit AAA enlargement. We sought to validate these preliminary observations at a population level.
Methods: All patients with asymptomatic AAA disease managed within the Veterans Affairs Health Care System between 2003 and 2013 were identified. Those with a concomitant diagnosis of diabetes mellitus who also received two abdominal imaging studies (computed tomography, magnetic resonance imaging, ultrasound) documenting the presence and size of an AAA, separated by at least 1 year, were included for review. Maximal AAA diameters were determined from radiologic reports. Further data acquisition was censored after surgical AAA repair when it was performed (Fig) . Comorbidities, active smoking status, and outpatient medication records (within 6 months of AAA diagnosis) were also queried. Yearly AAA enlargement rates, as a function of metformin treatment status, were compared using multivariate mixed-effects modeling with random-intercept and random-slope.
Results: A total of 13,834 patient records, with 58,833 radiographic reports, were abstracted (Fig) . The mean 6 standard deviation radiology follow-up was 4.2 6 2.6 years (Fig) . Average age at AAA diagnosis was 69.8 6 7.8 years, and 39.7% had a metformin prescription around that time. The mean AAA growth rate for the entire cohort was 1.3 6 1.6 mm/y. The unadjusted mean AAA growth rate was 1.2 6 1.9 mm/y for patients with a metformin prescription compared with 1.5 6 2.2 mm/y for those without (P < .001), a 20% reduction. When adjusted for comorbidities, this effect remained significant: metformin prescription was associated with a 0.2-mm reduction in yearly AAA growth rate (95% confidence interval, À0.26 to À0.14; P < .001). A secondary analysis performed on 7462 patients with an initial AAA size of 35 to 49 mm showed a similar inhibitory effect (1.4 6 2.0 vs 1.7 6 2.2 mm/y). Patient factors associated with an increased yearly AAA growth rate were baseline AAA size, metastatic solid tumors, current smoking, chronic obstructive pulmonary disease, and chronic renal disease. Factors associated with decreased growth rates included prescriptions for angiotensin receptor blockers or sulfonylureas and the presence of diabetes-related complications (Table) .
Conclusions: In a nationwide analysis of diabetic Veterans Affairs patients, prescription for metformin was associated with decreased AAA enlargement. Diabetic veteran AAA enlargement rates are less than those previously reported in nonveteran AAA populations. These findings support the conduct of a clinical trial testing the ability of metformin to limit AAA disease progression.
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Five-Year Results
Methods: Eighty-six patients (mean age, 59 years; 73% male) were prospectively enrolled at sites in the United States, Europe, and Australia from 2007 to 2012. Treatment was in the acute phase (14 days after symptom onset) in 55 patients and in the nonacute phase (>14 days; all treated within 90 days) in 31 patients. Five-year clinical and computed tomography follow-up was available for 89% of eligible patients.
Results: The 30-day all-cause mortality rate was 5.5% for acute and 3.2% for nonacute patients (P > .99). Five-year freedom from all-cause mortality was 80% 6 6% for acute and 71% 6 8% for nonacute patients (log-rank test, P ¼ .40). Five-year freedom from dissection-related mortality (including deaths of indeterminate relatedness to dissection repair) was 84% 6 6% for acute and 90% 6 6% for nonacute patients (log-rank test, P ¼ .55). Complete false lumen thrombosis in the thoracic aorta increased over time and was observed in 74% of acute and 59% of nonacute patients at 5 years. From before the procedure through 5 years, 
